Pharma investors—gene therapy is not the golden goose you think it is

Investors piling into gene therapy

In May, I posted about the need for investors to be wary about the profit potential for pharmaceutical products based on gene therapy. It refers to an article penned by me and Daniel O’Connor, founder and CEO of Trialsite News.

This is our conclusion, taken from the article:

The article begins:

News Gene therapy is the next great opportunity for pharma investors. That sentiment makes sense given the enormous capital flows, purported success of recent commercialized products and even initial public offerings as well as corporate acquisitions. But how much opportunity does this disruptive therapeutic area represent? Is the next wave of rapid growth around the corner or a big bubble? The paper, “Exploring the Economics of Gene Therapy Innovation and Price” lays out the pros and cons on behalf of the paper’s sponsor, Novartis…